Scientific deep-dive

Five Hundred Calories at One Lunch

Researchers weighed what 114 people ate at a free-access lunch. Three weeks into tirzepatide they ate 524.6 fewer calories, without any increase in conscious dietary restraint.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
6 min read·1 citation

Researchers sat 114 people down to a lunch they could eat as much of as they wanted, and weighed what they ate. Three weeks into tirzepatide, participants consumed 524.6 fewer calories at that meal than those on placebo.[1] The more interesting result is what the drug did not change: their conscious effort to restrict what they ate.

Why an ad libitum lunch

Most of what is known about how much people eat comes from food diaries, which are the weakest instrument in nutrition research. People under-report, forget, and record what they intended to eat. A laboratory meal with unlimited access, weighed before and after, removes all of that.

It buys objectivity at the cost of realism: one meal, in a laboratory, on a single day. What it measures it measures accurately.

Tirzepatide against placebo at week 3, in adults with a BMI of 27 to 50 and without diabetes.[1]
MeasureResult
Energy eaten at the lunch−524.6 kcal (95% CI −648.1 to −401.0), P < 0.0001
Overall appetiteDecreased
Food cravingsDecreased
Tendency to overeatDecreased
Perceived hungerDecreased
Reactivity to food in the environmentDecreased
Volitional restriction of dietary intakeNot changed

The row at the bottom is the finding

People ate five hundred calories less without trying harder not to.

Volitional restriction measures deliberate effort, such as consciously holding back and choosing less. It did not move. Everything that did move sits upstream of effort: how hungry people felt, how much they craved, how strongly food in the environment pulled at them.

That distinction is the whole argument about what these drugs are. A treatment that worked by strengthening willpower would show up as increased restraint. This one shows the opposite pattern: the pull weakened, and the effort required did not increase. It is the objective counterpart to what patients call food noise going quiet.

It also cuts against the framing that people on these drugs are taking a shortcut around discipline. On this evidence their discipline did not change; the thing it was being applied to got smaller.

The brain imaging, in the order it was found

The primary imaging outcome was not significant. Activation in response to the aggregated category of highly palatable food photographs (high-fat/high-sugar and high-fat/high-carbohydrate together) did not differ significantly from placebo at week 3. That is the result the analysis set out to find, and it did not find it.

A narrower finding did reach significance: activation to high-fat, high-sugar photographs specifically was reduced in four regions (the medial frontal and cingulate gyri, orbitofrontal cortex and hippocampus).

That is a sub-category within an imaging analysis, in named regions, after the aggregated outcome came back null. It is a reasonable finding to report and a poor one to lead with, and “brain scans show the drug reduces food reward” is how it will be summarized.

What limits it

  • Phase 1, 114 people, six weeks, with the primary measurement at week three. This is a mechanism study, not an efficacy trial.
  • One laboratory meal is not a day, a week, or a life. Whether a 500-calorie reduction at lunch persists across every meal is not what was measured.
  • The design is asymmetric. Tirzepatide and placebo were blinded; the liraglutide arm was open-label. Participants who know what they are taking report subjective outcomes differently, so that arm cannot be read alongside the other two on appetite measures.
  • Everyone was without diabetes, at a BMI between 27 and 50.

For why this effect fades over months, see why the appetite comes back; the proposed mechanism comes from work in mice.

Frequently Asked Questions

At a laboratory lunch with unlimited access, three weeks into treatment, participants ate 524.6 fewer calories than those on placebo. That is one weighed meal rather than a daily total.
The opposite pattern appeared. Volitional restriction of dietary intake, the measure of deliberate effort, did not change, while hunger, cravings, tendency to overeat and reactivity to food in the environment all decreased.
Because it separates a drug that makes eating less happen from one that makes people try harder. On this evidence the pull toward food weakened while the effort applied to resisting it stayed the same.
The primary imaging outcome, response to highly palatable food photographs as an aggregated category, was not statistically significant. A narrower analysis of high-fat, high-sugar photographs found reduced activation in four named regions.
It is a six-week phase 1 mechanism study in 114 people, measuring one meal in a laboratory. It explains something about how the drug works rather than establishing what it does over months.

References

  1. 1.Martin CK, Carmichael OT, Carnell S, et al. Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial Nature Medicine. 2025. PMID: 40555748.

Taste Got Better, Not Worse

People on these drugs routinely say food tastes wrong. A trial measured taste objectively, biopsied participants' tongues and scanned their brains, and found taste recognition improved.

6 min read

How Zepbound Works: Tirzepatide's Two Receptors, Appetite and Fat Loss

Zepbound (tirzepatide) switches on the GIP and GLP-1 receptors. Its label says it lowers calorie intake through appetite, slows stomach emptying mostly after the first dose, and improves insulin response. In SURMOUNT-1 body scans, about three-quarters of the weight lost was fat.

8 min read

How Does Phentermine Work? Does It Burn Fat or Suppress Appetite?

Two FDA labels describe phentermine differently: one says it likely lowers appetite through catecholamine release in the hypothalamus, the other says appetite suppression is unproven as its main action. No human trial shows it burns fat, and tolerance sets in within weeks.

6 min read

Does Vaping or Nicotine Cause Weight Loss? What Smokers' Data Show

No study shows vaping causes weight loss. Nicotine modestly curbs appetite and raises calorie burn, but smokers who switched to e-cigarettes gained weight, and quitting adds about 4.7 kg in a year. What the evidence shows, and where GLP-1 drugs fit.

10 min read

Jardiance and Farxiga for Weight Loss: How Much, and Why It Stops

Jardiance and Farxiga cause about 2 kg of weight loss in type 2 diabetes and less without it, and neither is approved for weight. Why appetite cancels most of the sugar lost in urine, the side effects, and how they compare with Wegovy and Zepbound.

10 min read

The Thing That Makes Regain Inevitable

Metabolic adaptation is the leading explanation for why weight loss plateaus and returns. A study asked whether tirzepatide interrupts it. In mice it did; in people it did not.

7 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

8.5

Gala

Moving between compounded and brand without changing seller

9.3

Embody

A flat compounded tirzepatide or semaglutide price at every dose, from a seller that names its pharmacies

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →